Population pharmacokinetics of favipiravir in patients with COVID‐19

The antiretroviral drug favipiravir (FPV) inhibits RNA‐dependent RNA polymerase. It has been developed for the treatment of the novel coronavirus (severe acute respiratory syndrome coronavirus 2) infection disease, coronavirus disease 2019 (COVID‐19). However, its pharmacokinetics in patients with C...

Descripción completa

Detalles Bibliográficos
Autores principales: Irie, Kei, Nakagawa, Atsushi, Fujita, Hirotoshi, Tamura, Ryo, Eto, Masaaki, Ikesue, Hiroaki, Muroi, Nobuyuki, Fukushima, Shoji, Tomii, Keisuke, Hashida, Tohru
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8420316/
https://www.ncbi.nlm.nih.gov/pubmed/34292670
http://dx.doi.org/10.1002/psp4.12685

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8420316/
https://www.ncbi.nlm.nih.gov/pubmed/34292670
http://dx.doi.org/10.1002/psp4.12685

Ejemplares similares